Related Experiment Videos
[Genetic polymorphism and susceptibility to cancer]
1Unité 301 INSERM, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1988
Summary
Proto-oncogene restriction fragment length polymorphisms (RFLPs) show varied associations with cancer susceptibility. Further research is needed to confirm if specific alleles contribute to tumor development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Proto-oncogenes are implicated in human tumor development.
- Proto-oncogene polymorphisms, specifically Restriction Fragment Length Polymorphisms (RFLPs), are common.
- RFLPs may be linked to cancer susceptibility.
Purpose of the Study:
- To investigate the association between proto-oncogene RFLPs and cancer susceptibility.
- To evaluate conflicting findings regarding c-ha-ras-l alleles and tumor risk.
- To explore associations between other proto-oncogene RFLPs and various cancers.
Main Methods:
- Review of existing population studies on proto-oncogene RFLPs and cancer.
- Analysis of Restriction Fragment Length Polymorphism (RFLP) data.
- Comparison of findings across different cancer types and proto-oncogenes.
Main Results:
- Confirmed associations between rare c-ha-ras-l alleles and breast cancer/lung adenocarcinoma.
- Refuted associations between rare c-ha-ras-l alleles and myelodysplasia, melanoma, colon adenocarcinoma.
- Identified significant associations between other proto-oncogene RFLPs (c-mos, c-raf, L-myc) and specific cancers (breast, non-Hodgkin's lymphoma, lung carcinoma metastasis).
Conclusions:
- The role of proto-oncogene RFLPs in cancer susceptibility is complex and requires further investigation.
- Specific RFLPs may contribute to the development of certain tumors, but findings are controversial.
- Extended studies are necessary to validate these associations and understand their contribution to oncogenesis.